<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Breast Cancer Res Treat</journal-id><journal-id journal-id-type="iso-abbrev">Breast Cancer Res Treat</journal-id><journal-title-group><journal-title>Breast Cancer Research and Treatment</journal-title></journal-title-group><issn pub-type="ppub">0167-6806</issn><issn pub-type="epub">1573-7217</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39417908</article-id><article-id pub-id-type="pmc">PMC11785642</article-id>
<article-id pub-id-type="publisher-id">7517</article-id><article-id pub-id-type="doi">10.1007/s10549-024-07517-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>The use of a clip prior to neoadjuvant chemotherapy for breast cancer with microcalcifications may not always be required</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0009-0009-2091-6749</contrib-id><name><surname>Talec</surname><given-names>Henri</given-names></name><address><email>henri.talec@etud.univ-angers.fr</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Aub&#x000e9;</surname><given-names>Christophe</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Guerin-Charbonnel</surname><given-names>Catherine</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Berge</surname><given-names>Pierre</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0250ngj72</institution-id><institution-id institution-id-type="GRID">grid.411147.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 0472 0283</institution-id><institution>Department of Radiology and Medical Imaging, </institution><institution>University Hospital, </institution></institution-wrap>49100 Angers, France </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01m6as704</institution-id><institution-id institution-id-type="GRID">grid.418191.4</institution-id><institution-id institution-id-type="ISNI">0000 0000 9437 3027</institution-id><institution>Institut de Canc&#x000e9;rologie de l&#x02019;Ouest, </institution></institution-wrap>44805 Saint-Herblain, France </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01m6as704</institution-id><institution-id institution-id-type="GRID">grid.418191.4</institution-id><institution-id institution-id-type="ISNI">0000 0000 9437 3027</institution-id><institution>Institut de Canc&#x000e9;rologie de l&#x02019;Ouest, </institution></institution-wrap>49055 Angers, France </aff></contrib-group><pub-date pub-type="epub"><day>17</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>17</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>209</volume><issue>3</issue><fpage>585</fpage><lpage>593</lpage><history><date date-type="received"><day>10</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>4</day><month>10</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">Neoadjuvant chemotherapy is now a common first line therapy for breast cancer. International guidelines recommend placement of a clip before commencement of therapy to assist with localizing the tumor bed in the event of excellent response&#x02014;this takes up time and resources. The microcalcifications associated usually persist after chemotherapy and could serve as an alternative marker. We investigated to determine prognostic criteria to avoid the need for a marker clip before neoadjuvant chemotherapy for breast tumors associated with microcalcifications.</p></sec><sec><title>Methods</title><p id="Par2">We performed a 7&#x000a0;year single-center bi-site retrospective analytical observational study of 88 women with calcified breast carcinoma treated by neoadjuvant chemotherapy at our bi-site institution between September 2015 and September 2022. This study includied two groups (clip-free tumor localization vs. clip-free tumor non-localization), and investigating quantitative and qualitative predictive factors. The clip-free tumor localization after neoadjuvant chemotherapy was defined by the visibility of residual calcifications on both views of the pre-operative mammogram on the day of or the day prior to surgery.</p></sec><sec><title>Results</title><p id="Par3">The mean age of the 88 women included in our population was 52.8&#x000a0;years (&#x000b1;&#x02009;12.7&#x000a0;years standard deviation). Of the 90 tumors with microcalcifications, 64 carcinomas (71.1%) were localizable with no marker clip after neoadjuvant chemotherapy. The main predictive factors significantly associated with clip-free tumor localization were number of calcifications&#x02009;&#x0003e;&#x02009;10 (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001), grade 2 tumor (<italic>P</italic>&#x02009;=&#x02009;0.003) with a probability of locating tumor after neoadjuvant chemotherapy of 97.9%, 95% CI&#x02009;[95.6; 99.0].</p></sec><sec><title>Conclusion</title><p id="Par4">More than 10 microcalcifications in a grade 2 breast tumor at the initial diagnosis may obviate the need for a marker clip.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Breast cancer</kwd><kwd>Microcalcification</kwd><kwd>Marker clip</kwd><kwd>Mammography</kwd></kwd-group><funding-group><award-group><funding-source><institution>Universit&#x000e9; d'Angers</institution></funding-source></award-group><open-access><p>Open access funding provided by Universit&#x000e9; d'Angers.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par16">Neoadjuvant chemotherapy is now a common first line therapy for high risk breast cancers that progress rapidly or are inaccessible to immediate conservative treatment, and can result in better surgical options with increased breast conservation (conservative treatment rather than radical mastectomy) [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par17">When neoadjuvant chemotherapy is initiated for a breast tumor, the carcinomatous tissue component may undergo partial or complete regression (some tumors do not respond or may indeed progress). International guidelines recommend placement of a marker clip inside the tumor before commencement of chemotherapy to facilitate pre-operative radiologic wire localization in the event of excellent response. This method is considered reliable and safe [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>], but has certain disadvantages such as possible complications, medical time consuming and a relatively high material cost of $85 to $320 per clip [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par18">When microcalcifications are associated with the tumor, they usually show no morphologic change after chemotherapy. They may increase or decrease in number, more rarely disappear [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>], and so they could be used as a radiographic marker [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR7">7</xref>], which could then be substituted for the marker clip (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Invasive carcinome of no special type (ICNST) grade 2 with groups of microcalcifications&#x02009;&#x0003e;&#x02009;10 units on mammography and ultrasound before (<bold>A</bold>, <bold>B</bold>) and after (<bold>C</bold>, <bold>D</bold>) neoadjuvant chemotherapy. Note the complete regression of the carcinomatous tissue component and the persistence of the micro-calcifications making it possible to place pre-operative radiologic wire localization after therapy (<bold>E</bold>, <bold>F</bold>)</p></caption><graphic xlink:href="10549_2024_7517_Fig1_HTML" id="MO1"/></fig></p><p id="Par19">At present, no criteria have been formally defined for using or not using a marker clip prior to neoadjuvant chemotherapy for tumors with microcalcifications.</p><p id="Par20">This raises the question of the systematic need for a marker clip, and the definition of objective criteria for determining whether it is necessary.</p><p id="Par21">To the best of our knowledge, no studies specifically addressing this issue have been reported in the literature.</p><p id="Par22">The main objective of our study was to determine the prognostic criteria for calcifications, tumors, or patients, to avoid the need for a marker clip. The secondary objective was to evaluate the inter-observer reproducibility of these criteria.</p></sec><sec id="Sec2"><title>Methods</title><p id="Par23">Access to health information was approved by an ethics committee (#2022-158, Ethic commitee CHU d&#x02019;Angers). All patients had approved the re-use of their electronically recorded data. Guidelines for reporting this study were derived from the &#x0201c;Strengthening the Reporting of Observational Studies in Epidemiology&#x0201d; (STROBE) statement.</p><sec id="Sec3"><title>Study design and population</title><p id="Par24">We performed a retrospective single-center bi-site analytic observational cohort study of consecutive patients with a breast carcinoma treated by neoadjuvant chemotherapy admitted during 84&#x000a0;month period (September 1, 2015 to September 30, 2022) at our bi site oncology institution. Inclusion criteria were women older than 18&#x000a0;years, breast carcinoma confirmed by diagnostic micro or macrobiopsy, and treated by neoadjuvant chemotherapy. Exclusion criteria were the absence of one or more suspicious microcalcifications associated tumor, missing mammographic or histologic data. This study included two groups (clip-free tumor localization vs. clip-free tumor non-localization) with research into quantitative and qualitative predictive factors.</p><p id="Par25">The primary endpoint was to assess the no need for a marker clip after neoadjuvant chemotherapy, determined on the console by the visibility of residual calcifications in both the un-magnified pre-operative mammograms taken on the day of or the day prior to surgery.</p><p id="Par26">The secondary endpoint included evaluation of inter-observer agreement for statistically significant predictive factors and the primary endpoint.</p></sec><sec id="Sec4"><title>Data collection and outcome assessment</title><p id="Par27">All tumors of our studies received a marker clip according to the international guidelines. For each patient, all data relating to potential predictive factors were collected prior to neoadjuvant chemotherapy. Mammographic features were collected by console reading on craniocaudal, mediolateral oblique and magnified diagnostic mammograms. The histologic results were collected on original histology reports from the diagnostic biopsy, simulating a real-life condition.</p><p id="Par28">Patient data were age and breast density (BI-RADS 5th Edition: A, B, C, D). Calcification data were group size (millimeters); number of calcifications associated with the tumor; suspicious morphology (BI-RADS 5th Edition: amorphous, fine pleiomorphic, coarse heterogenous, linear or brancher, round or punctiform); distribution (BI-RADS 5th Edition: grouped, diffuse, linear, regional, segmental); contrast with the underlying breast density; spread or not beyond the mass. Tumor data were size (millimeters); histology: invasive carcinome of no special type (ICNST), invasive lobular carcinoma (ILC), other, with or without in-situ associated; grade; percentage of hormonal receptors; HER2 status: positive (defined as 3&#x02009;+&#x02009;staining or 2&#x02009;+&#x02009;FISH amplified) or negative; Ki67 proliferation index.</p><p id="Par29">The BI-RADS 5th edition lexicon was used, and all features were double-read by both a radiology resident (H.T) and a senior radiologist (P.B.) specializing in senology (4&#x000a0;years&#x02019; experience). In the event of mismatch, a joint re-reading was carried out to reach a consensus, and statistic analyses were carried out based on the consensus. Agreement was measured a posteriori, based on the initial analyses by each reader, on mammographic variables that were statistically significant, and on the primary endpoint.</p></sec><sec id="Sec5"><title>Statistical analysis</title><p id="Par30">For all tests, statistic significance level was set at 5%. Analyses were performed (C.G.) with R software [R Core Team (2014). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL: <ext-link ext-link-type="uri" xlink:href="http://www.R-project.org/">http://www.R-project.org/</ext-link>.]</p><p id="Par31">The approach focused on the tumor studied, and tumors from the same patient were considered independent in terms of the features observed.</p><p id="Par32">Quantitative variables were described by median, inter-quartile range, minimum, maximum, mean and standard deviation, and qualitative variables by number and percentage.</p><p id="Par33">The impact of the different variables on the need for a clip was estimated using univariable and multivariable logistic models.</p><p id="Par34">Stepwise procedure based on the Akaike Information Criterion (AIC) was used to define an optimal multivariable model, all variables with a univariable <italic>P</italic> value&#x02009;&#x0003c;&#x02009;0.15 were entered into the initial model.</p><p id="Par35">An unweighted Cohen&#x02019;s kappa was used to agreement measure of qualitative variables, and intra-class correlation for ordinal variables.</p><p id="Par36">Following this last analysis, a multivariable model with only objective variables and a minimal multivariable model were built.</p></sec></sec><sec id="Sec6"><title>Results</title><sec id="Sec7"><title>Patient demographics</title><p id="Par37">After reviewing 240 medical records of adult women with breast carcinoma treated by neoadjuvant chemotherapy and excluding 125 patients with no suspicious calcifications associated (52% of patients), 25 patients with missing mammographic data (10% of patients) and 2 patients with missing histologic data (1% of patients), the population included 88 patients for a study sample of 90 tumors (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref><italic>)</italic>.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Flow-chart</p></caption><graphic xlink:href="10549_2024_7517_Fig2_HTML" id="MO2"/></fig></p><p id="Par38">The mean age was 52.8&#x000a0;years (&#x000b1;&#x02009;12.7&#x000a0;years). Type A breast density represented 9% of cases (8/90), type B 57% (51/90), type C 30% (27/90), and type D 4.5% (4/90): Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Demographic table</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Parameter</th><th align="left">Value</th></tr></thead><tbody><tr><td align="left">No of participants</td><td align="left">88</td></tr><tr><td align="left">Age (years)*</td><td align="left">52.84&#x02009;&#x000b1;&#x02009;12.69</td></tr><tr><td align="left">Breast density</td><td align="left"/></tr><tr><td align="left">&#x000a0;A</td><td align="left">8 (8.89%)</td></tr><tr><td align="left">&#x000a0;B</td><td align="left">51 (56.67%)</td></tr><tr><td align="left">&#x000a0;C</td><td align="left">27 (30.00%)</td></tr><tr><td align="left">&#x000a0;D</td><td align="left">4 (4.44%)</td></tr><tr><td align="left">Mass size (mm)*</td><td align="left">26.31&#x02009;&#x000b1;&#x02009;13.06</td></tr><tr><td align="left">Invasive or in-situ</td><td align="left"/></tr><tr><td align="left">&#x000a0;Invasive</td><td align="left">51 (56.67%)</td></tr><tr><td align="left">&#x000a0;Both</td><td align="left">39 (43.33%)</td></tr><tr><td align="left">Histology</td><td align="left"/></tr><tr><td align="left">&#x000a0;ICNST</td><td align="left">86 (95.56%)</td></tr><tr><td align="left">&#x000a0;ILC</td><td align="left">3 (3.33%)</td></tr><tr><td align="left">&#x000a0;Other</td><td align="left">1 (1.11%)</td></tr><tr><td align="left">Grade</td><td align="left"/></tr><tr><td align="left">&#x000a0;1</td><td align="left">0 (0.0%)</td></tr><tr><td align="left">&#x000a0;2</td><td align="left">47 (52.22%)</td></tr><tr><td align="left">&#x000a0;3</td><td align="left">43 (47.78%)</td></tr><tr><td align="left">ER (%)</td><td align="left"/></tr><tr><td align="left">&#x02009;&#x0003c;&#x02009;10</td><td align="left">34 (37.78%)</td></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;10%</td><td align="left">56 (62.22%)</td></tr><tr><td align="left">PR (%)</td><td align="left"/></tr><tr><td align="left">&#x02009;&#x0003c;&#x02009;10%</td><td align="left">46 (51.11%)</td></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;10%</td><td align="left">44 (48.89%)</td></tr><tr><td align="left">HER2</td><td align="left"/></tr><tr><td align="left">&#x000a0;Negative</td><td align="left">43 (47.78%)</td></tr><tr><td align="left">&#x000a0;Positive**</td><td align="left">47 (52.22%)</td></tr><tr><td align="left">Ki67 (%)*</td><td align="left">30.63&#x02009;&#x000b1;&#x02009;22.29</td></tr><tr><td align="left">&#x000a0;<italic>nb. NA</italic></td><td align="left"><italic>9</italic></td></tr><tr><td align="left">Group of Ca size (mm)*</td><td align="left">25.71&#x02009;&#x000b1;&#x02009;22.20</td></tr><tr><td align="left">Ca number</td><td align="left"/></tr><tr><td align="left">&#x02009;&#x02264;&#x02009;10</td><td align="left">18 (20.00%)</td></tr><tr><td align="left">&#x02009;&#x0003e;&#x02009;10</td><td align="left">72 (80.00%)</td></tr><tr><td align="left">Morphology</td><td align="left"/></tr><tr><td align="left">&#x000a0;Amorphous</td><td align="left">19 (21.11%)</td></tr><tr><td align="left">&#x000a0;Fine pleiomorphic</td><td align="left">19 (21.11%)</td></tr><tr><td align="left">&#x000a0;Coarse heterogeneous</td><td align="left">19 (21.11%)</td></tr><tr><td align="left">&#x000a0;Linear or branched</td><td align="left">16 (17.78%)</td></tr><tr><td align="left">&#x000a0;Round or punctiform</td><td align="left">17 (18.89%)</td></tr><tr><td align="left">Distribution</td><td align="left"/></tr><tr><td align="left">&#x000a0;Grouped</td><td align="left">40 (44.44%)</td></tr><tr><td align="left">&#x000a0;Diffuse</td><td align="left">4 (4.44%)</td></tr><tr><td align="left">&#x000a0;Linear</td><td align="left">7 (7.78%)</td></tr><tr><td align="left">&#x000a0;Regional</td><td align="left">20 (22.22%)</td></tr><tr><td align="left">&#x000a0;Segmental</td><td align="left">19 (21.11%)</td></tr><tr><td align="left">Contrast Ca/breast</td><td align="left"/></tr><tr><td align="left">&#x000a0;Weak</td><td align="left">34 (37.78%)</td></tr><tr><td align="left">&#x000a0;Strong</td><td align="left">56 (62.22%)</td></tr><tr><td align="left">Ca spread</td><td align="left"/></tr><tr><td align="left">&#x000a0;No</td><td align="left">48 (53.33%)</td></tr><tr><td align="left">&#x000a0;Yes</td><td align="left">42 (46.67%)</td></tr></tbody></table><table-wrap-foot><p>Unless otherwise specified, data are categoric variables presented as numbers, with percentages in parentheses</p><p><italic>Ca</italic>&#x02009;calcifications, <italic>ER</italic>&#x02009;estrogen receptor, <italic>HER2</italic>&#x02009;human epidermal growth factor receptor-2, <italic>ICNST</italic>&#x02009;invasive carcinome of no special type, <italic>ILC</italic>&#x02009;invasive lobular carcinoma, <italic>PR</italic>&#x02009;progesterone receptor</p><p>*Data are means&#x02009;&#x000b1;&#x02009;SDs, **3&#x02009;+&#x02009;stained or 2&#x02009;+&#x02009;FISH amplified</p></table-wrap-foot></table-wrap></p><p id="Par39">The mean size of the 90 tumors was 26.3&#x000a0;mm, with 57% invasive (51/90) and 43% invasive-in situ (39/90). Most tumors (96%) were ICNST (86/90), versus 3% ILC (3/90), and only 1 cancer (1%) with a different histologic type (metaplastic carcinoma). There were no grade 1 tumors in our population, grade 2 made up 52% (47/90) and grade 3 48% (43/90) of carcinomas. 62% of the tumors had&#x02009;&#x02265;&#x02009;10% estrogen receptors (56/90), 49% had&#x02009;&#x02265;&#x02009;10% progesterone receptors (44/90). HER2 positive was reported in 52% of cases (47/90) and the mean Ki67 value was 31% (SD: 22).</p><p id="Par40">The mean size of calcification groups was 25.7&#x000a0;mm (SD: 22). Eighty percent of the groups had more than 10 calcifications (72/90). Amorphous, fine pleomorphic, and coarse heterogeneous morphologies predominated in equal proportions: 21% of groups of calcifications (19/90), fine linear or linear-branching morphology predominated in 18% of the groups (16/90), and round or punctiform morphology in 19% of the groups (17/90).</p><p id="Par41">Diffuse distribution was found in 4% of cases (4/90), grouped distribution in 44% (40/90), linear distribution in 8% (7/90), regional distribution in 22% (20/90), and segmental distribution in 21% (19/90). Calcifications contrast with underlying breast density was considered strong in 62% of cases (56/90).</p><p id="Par42">Groups of microcalcifications spread beyond the mass in 47% of cases (42/90).</p><p id="Par43">The average delay between diagnostic mammography and pre-operative mammography was 184&#x000a0;days.</p></sec><sec id="Sec8"><title>Prognostic criteria for clipless localization</title><sec id="Sec9"><title>Univariable analysis</title><p id="Par44">No patient feature (age; breast density) was statistically significant for clip-free tumor localization after neoadjuvant chemotherapy: Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref><italic>.</italic><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Univariable and multivariable results for available parameters; parameters included in stepwise multivariable model are in bold font</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Parameter</th><th align="left" rowspan="2">Clip-free tumor non localization (<italic>n</italic>&#x02009;=&#x02009;26)</th><th align="left" rowspan="2">Clip-free tumor localization (<italic>n</italic>&#x02009;=&#x02009;64)</th><th align="left" colspan="2">Univariable results</th><th align="left" colspan="2">Multivariable results</th></tr><tr><th align="left">Odds-ratio (IC95%)</th><th align="left"><italic>P</italic> value</th><th align="left">Odds-ratio (IC95%)</th><th align="left"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left">Grade</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;2</td><td align="left">7 (26.92%)</td><td align="left">40 (62.50%)</td><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;3</td><td align="left">19 (73.08%)</td><td align="left">24 (37.50%)</td><td align="left">0.22 [0.08; 0.58]</td><td char="." align="char"><bold>0.0032</bold></td><td align="left">0.01 [0.00; 0.13]</td><td char="." align="char"><bold><italic>0.0021</italic></bold></td></tr><tr><td align="left">Distribution</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Grouped</td><td align="left">17 (65.38%)</td><td align="left">23 (35.94%)</td><td align="left"/><td char="." align="char"/><td align="left" colspan="2"><italic>*Reference category: grouped or diffuse or linear</italic></td></tr><tr><td align="left">&#x000a0;Diffuse</td><td align="left">4 (15.38%)</td><td align="left">0 (0.00%)</td><td align="left">&#x02013;</td><td char="." align="char">&#x02013;</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Linear</td><td align="left">2 (7.69%)</td><td align="left">5 (7.81%)</td><td align="left">1.85 [0.35; 14.00]</td><td char="." align="char">0.4930</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Regional</td><td align="left">2 (7.69%)</td><td align="left">18 (28.12%)</td><td align="left">6.65 [1.62; 45.48]</td><td char="." align="char"><bold>0.0195</bold></td><td align="left">28.15 [3.07; 526.22]</td><td char="." align="char"><bold><italic>0.0097</italic></bold></td></tr><tr><td align="left">&#x000a0;Segmental</td><td align="left">1 (3.85%)</td><td align="left">18 (28.12%)</td><td align="left">13.30 [2.38; 251.00]</td><td char="." align="char"><bold>0.0162</bold></td><td align="left">51.06 [3.27; 2114.49]</td><td char="." align="char"><bold><italic>0.0144</italic></bold></td></tr><tr><td align="left">Contrast Ca/breast</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Weak</td><td align="left">14 (53.85%)</td><td align="left">20 (31.25%)</td><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Strong</td><td align="left">12 (46.15%)</td><td align="left">44 (68.75%)</td><td align="left">2.57 [1.01; 6.65]</td><td char="." align="char"><bold>0.0481</bold></td><td align="left">12.36 [1.99; 131.75]</td><td char="." align="char"><bold><italic>0.0146</italic></bold></td></tr><tr><td align="left">Number of Ca</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x02009;&#x02264;&#x02009;10</td><td align="left">16 (61.54%)</td><td align="left">2 (3.12%)</td><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x02009;&#x0003e;&#x02009;10</td><td align="left">10 (38.46%)</td><td align="left">62 (96.88%)</td><td align="left">49.60 [11.88; 346.55]</td><td char="." align="char"><bold>&#x02009;&#x0003c;&#x02009;0.0001</bold></td><td align="left">835.61 [41.48; 79,035.23]</td><td char="." align="char"><bold><italic>0.0003</italic></bold></td></tr><tr><td align="left">Ca spread</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;No</td><td align="left">19 (73.08%)</td><td align="left">29 (45.31%)</td><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Yes</td><td align="left">7 (26.92%)</td><td align="left">35 (54.69%)</td><td align="left">3.28 [1.25; 9.39]</td><td char="." align="char"><bold>0.0196</bold></td><td align="left">0.11 [0.01; 0.69]</td><td char="." align="char"><bold><italic>0.0319</italic></bold></td></tr><tr><td align="left">Invasive/in situ</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Invasive</td><td align="left">18 (69.23%)</td><td align="left">33 (51.56%)</td><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Both</td><td align="left">8 (30.77%)</td><td align="left">31 (48.44%)</td><td align="left">2.11 [0.82; 5.80]</td><td char="." align="char"><bold>0.1290</bold></td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">ER (%)</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x02009;&#x0003c;&#x02009;10</td><td align="left">13 (50.00%)</td><td align="left">21 (32.81%)</td><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;10%</td><td align="left">13 (50.00%)</td><td align="left">43 (67.19%)</td><td align="left">2.05 [0.81; 5.24]</td><td char="." align="char"><bold>0.1306</bold></td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Morphology</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Amorphous</td><td align="left">8 (30.77%)</td><td align="left">11 (17.19%)</td><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Fine pleiomorphic</td><td align="left">6 (23.08%)</td><td align="left">13 (20.31%)</td><td align="left">1.58 [0.42; 6.17]</td><td char="." align="char">0.5023</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Coarse heterogeneous</td><td align="left">2 (7.69%)</td><td align="left">17 (26.56%)</td><td align="left">6.18 [1.27; 46.35]</td><td char="." align="char"><bold>0.0385</bold></td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Linear or branched</td><td align="left">1 (3.85%)</td><td align="left">15 (23.44%)</td><td align="left">10.91 [1.65; 218.14]</td><td char="." align="char"><bold>0.0349</bold></td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Round or punctiform</td><td align="left">9 (34.62%)</td><td align="left">8 (12.50%)</td><td align="left">0.65 [0.17; 2.41]</td><td char="." align="char">0.5164</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Underlying breast density of Ca</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Strong</td><td align="left">16 (61.54%)</td><td align="left">20 (31.25%)</td><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Weak</td><td align="left">10 (38.46%)</td><td align="left">44 (68.75%)</td><td align="left">3.52 [1.38; 9.37]</td><td char="." align="char"><bold>0.0095</bold></td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Age (years)*</td><td align="left">51.62&#x02009;&#x000b1;&#x02009;12.30</td><td align="left">53.34&#x02009;&#x000b1;&#x02009;12.91</td><td align="left">1.01 [0.98; 1.05]</td><td char="." align="char">0.5566</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Breast density</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;A</td><td align="left">1 (3.85%)</td><td align="left">7 (10.94%)</td><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;B</td><td align="left">13 (50.00%)</td><td align="left">38 (59.38%)</td><td align="left">0.42 [0.02; 2.68]</td><td char="." align="char">0.4340</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;C</td><td align="left">10 (38.46%)</td><td align="left">17 (26.56%)</td><td align="left">0.24 [0.01; 1.66]</td><td char="." align="char">0.2148</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;D</td><td align="left">2 (7.69%)</td><td align="left">2 (3.12%)</td><td align="left">0.14 [0.00; 2.24]</td><td char="." align="char">0.1837</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Mass size (mm)*</td><td align="left">24.23&#x02009;&#x000b1;&#x02009;14.78</td><td align="left">27.16&#x02009;&#x000b1;&#x02009;12.32</td><td align="left">1.02 [0.98; 1.06]</td><td char="." align="char">0.3378</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">PR (%)</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x02009;&#x0003c;&#x02009;10</td><td align="left">14 (53.85%)</td><td align="left">32 (50.00%)</td><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;10%</td><td align="left">12 (46.15%)</td><td align="left">32 (50.00%)</td><td align="left">1.17 [0.47; 2.94]</td><td char="." align="char">0.7409</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">HER2</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Negative</td><td align="left">15 (57.69%)</td><td align="left">28 (43.75%)</td><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Positive**</td><td align="left">11 (42.31%)</td><td align="left">36 (56.25%)</td><td align="left">1.75 [0.70; 4.49]</td><td char="." align="char">0.2324</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Ki67 (%)*</td><td align="left">33.17&#x02009;&#x000b1;&#x02009;22.61</td><td align="left">29.62&#x02009;&#x000b1;&#x02009;22.27</td><td align="left">0.99 [0.97; 1.01]</td><td char="." align="char">0.5161</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">Group of Ca size (mm)*</td><td align="left">23.35&#x02009;&#x000b1;&#x02009;33.46</td><td align="left">26.67&#x02009;&#x000b1;&#x02009;15.77</td><td align="left">1.01 [0.99; 1.03]</td><td char="." align="char">0.5196</td><td align="left"/><td char="." align="char"/></tr></tbody></table><table-wrap-foot><p>Unless otherwise specified, data are categoric variables presented as numbers, with percentages in parentheses</p><p><italic>Ca</italic>&#x02009;calcifications, <italic>ER</italic>&#x02009;estrogen receptor, <italic>HER2</italic>&#x02009;human epidermal growth factor receptor-2, <italic>PR</italic>&#x02009;progesterone receptor</p><p>*Data are means&#x02009;&#x000b1;&#x02009;SDs, **3&#x02009;+&#x02009;stained or 2&#x02009;+&#x02009;FISH amplified</p></table-wrap-foot></table-wrap></p><p id="Par45">Except grade, no tumor feature (size; histology; PR; ER; HER2; Ki67) was statistically significant for clipless localization after neoadjuvant chemotherapy. Only grade 3 (<italic>reference</italic>: grade 2) was not in favor of clipless tumor localization (<italic>P</italic>&#x02009;=&#x02009;0.003, OR&#x02009;&#x0003c;&#x02009;1)<italic>.</italic></p><p id="Par46">A group of microcalcifications composed strictly of more than 10 units was associated with clip-free tumor localization after neoadjuvant chemotherapy (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001)<italic>.</italic></p><p id="Par47">Regional or segmental distribution was associated with clip-free tumor localization (<italic>ref</italic>: grouped distribution), with respectively <italic>P</italic>&#x02009;=&#x02009;0.02 and <italic>P</italic>&#x02009;=&#x02009;0.02. Strong calcifications contrast with the underlying mammary gland was associated with clip-free tumor localization (<italic>P</italic>&#x02009;=&#x02009;0.048). Spread of calcifications beyond the mass was associated with tumor localization (<italic>P</italic>&#x02009;=&#x02009;0.02). Coarse heterogeneous and fine linear or linear-branching morphologies were associated with clip-free tumor localization (<italic>ref</italic>: amorphous morphology), with respectively <italic>P</italic>&#x02009;=&#x02009;0.04 and <italic>P</italic>&#x02009;=&#x02009;0.04. No statistically significant differences were found for fine pleiomorphic or punctuate predominant morphologies. Group of microcalcifications size was not statistically significant for clip-free localization (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p></sec><sec id="Sec10"><title>Multivariable analysis</title><p id="Par48">Grade 3 tumor (<italic>P</italic>&#x02009;=&#x02009;0.02), regional distribution (<italic>P</italic>&#x02009;=&#x02009;0.001) and segmental distribution (<italic>ref</italic>: grouped, diffuse or linear distribution) (<italic>P</italic>&#x02009;=&#x02009;0.01), strong contrast of calcifications (<italic>P</italic>&#x02009;=&#x02009;0.01), number of calcifications&#x02009;&#x0003e;&#x02009;10 units (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) and calcifications spread (<italic>P</italic>&#x02009;=&#x02009;0.03) were associated with tumor localization in the stepwise multivariable model (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p></sec></sec><sec id="Sec11"><title>Inter-observer reproducibility</title><p id="Par49">Agreement of clip-free tumor localization after neo-adjuvant chemotherapy was total with a coefficient of 1: Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>.<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Inter-observer reproducibility</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Parameter</th><th align="left">Agreement coefficient</th></tr></thead><tbody><tr><td align="left">Clip-free tumor localization</td><td align="left">1</td></tr><tr><td align="left">Number Ca</td><td align="left"/></tr><tr><td align="left">&#x02009;&#x02264;&#x02009;10 vs.&#x02009;&#x0003e;&#x02009;10</td><td align="left">0.81</td></tr><tr><td align="left">Distribution</td><td align="left"/></tr><tr><td align="left">&#x000a0;Regional</td><td align="left">0.41</td></tr><tr><td align="left">&#x000a0;Segmental</td><td align="left">0.28</td></tr><tr><td align="left">Contrast Ca/breast</td><td align="left">0.61</td></tr><tr><td align="left">Ca spread</td><td align="left">0.87</td></tr></tbody></table><table-wrap-foot><p><italic>Ca</italic>&#x02009;calcifications</p></table-wrap-foot></table-wrap></p><p id="Par50">After categorizing the number of calcifications in the group into]0;10] and&#x02009;&#x0003e;&#x02009;10, agreement was estimated as strong with a coefficient of 0.81.</p><p id="Par51">Agreement of regional or segmental calcification distribution was moderate and weak, with coefficients of 0.41 and 0.28, respectively.</p><p id="Par52">The agreement of contrast factor was high at 0.61, while that for spread calcification factor was strong at 0.87.</p></sec><sec id="Sec12"><title>Multivariable model based on objective parameter (strong agreement)</title><p id="Par53">Grade 3 tumors (<italic>P</italic>&#x02009;=&#x02009;0.007) and a group of microcalcifications composed strictly of more than 10 units (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001) were significantly associated with tumor localization after neoadjuvant chemotherapy in the stepwise multivariable model with objective parameters (histologic and mammographic parameters showing strong inter-observer agreement): Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>.<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Multivariable model with objective parameters</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Parameter</th><th align="left">Odds-ratio (IC95%)</th><th align="left"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left">Number of Ca</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02009;&#x0003e;&#x02009;10 vs.&#x02009;&#x02264;&#x02009;10</td><td align="left">204.37 [24.08; 5238.98]</td><td align="left">&#x02009;&#x0003c;&#x02009;0.0001</td></tr><tr><td align="left">Grade</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;3 vs. 2</td><td align="left">0.05 [0.00; 0.30]</td><td align="left">0.0065</td></tr><tr><td align="left">Ca spread</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Yes vs. no</td><td align="left">0.60 [0.13; 2.43]</td><td align="left">0.4843</td></tr></tbody></table><table-wrap-foot><p><italic>Ca</italic>&#x02009;calcifications</p></table-wrap-foot></table-wrap></p><p id="Par54">Retaining only significant parameters, a minimal multivariable model can be derived including only grade and number of microcalcifications&#x02009;&#x0003e;&#x02009;10: Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>.<table-wrap id="Tab5"><label>Table&#x000a0;5</label><caption><p>Minimal multivariable model</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Parameter</th><th align="left">Odds-ratio (IC95%)</th><th align="left"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left">Number of Ca</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x02009;&#x0003e;&#x02009;10 vs.&#x02009;&#x02264;&#x02009;10</td><td align="left">153.90 [21.52; 3530.88]</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.0001</td></tr><tr><td align="left">Grade</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;3 vs. 2</td><td align="left">0.06 [0.00; 0.31]</td><td char="." align="char">0.0074</td></tr></tbody></table><table-wrap-foot><p><italic>Ca</italic>&#x02009;calcifications</p></table-wrap-foot></table-wrap></p><p id="Par55">Based on this model, the probability of locating a grade 2 tumor with more than 10 calcifications after neoadjuvant chemotherapy is 97.9%, 95% CI&#x02009;[95.6; 99.0].</p></sec></sec><sec id="Sec13"><title>Discussion</title><p id="Par56">To the best of our knowledge, no similar studies specifically addressing criteria for not using a marker clip in breast tumor with calcifications have been reported in the literature. We identified various factors to favor clip-free tumor localization after neoadjuvant chemotherapy, such as a group of microcalcifications composed strictly of more than 10 units (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001), grade 2 tumors (<italic>P</italic>&#x02009;=&#x02009;0.003), regional (<italic>P</italic>&#x02009;=&#x02009;0.02) or segmental (<italic>P</italic>&#x02009;=&#x02009;0.02) distribution, strong contrast of calcifications on underlying breast density (<italic>P</italic>&#x02009;=&#x02009;0.048), and spread of calcifications beyond the mass (<italic>P</italic>&#x02009;=&#x02009;0.001).</p><p id="Par57">The number of calcifications associated with the breast tumor at initial diagnosis is a fundamental predictive factor for clip-free localization. A group of microcalcifications composed strictly of more than 10 units is significantly associated with its localizability, with a probability of locating grade 2 tumors after neoadjuvant chemotherapy of 97.9%, 95% CI&#x02009;[95.6; 99.0].</p><p id="Par58">This study suggests that a grade 3 tumor is a limiting factor for clip-free localization. We explain this by the aggressive and evolutive character of grade 3 tumors, resulting in an accelerated response to chemotherapy, making possible partial or complete disappearance of calcifications [<xref ref-type="bibr" rid="CR17">17</xref>]. Not surprisingly, strong calcification contrast with the underlying breast density, because of their better visibility, is statistically significant in both univariable and multivariable analyses.</p><p id="Par59">All objective variables in this study are reproducible with strong agreement like number of calcifications (coefficient of 0.81) and clip-free tumor localization (coefficient of 1). Indeed, all that was required for the primary endpoint was observation of one residual microcalcification after neoadjuvant chemotherapy to locate the tumor, just as a marker clip would do.</p><p id="Par60">Factors weakly associated with clip-free localization, such as distribution, are less reproducible, as observed in daily practice. In our study, 43.3% (39/90) of patients had a grade 2 breast tumor with a group of microcalcifications composed strictly of more than 10 units, and our population was comparable to cohorts observed in other studies of breast tumors with microcalcifications treated with neoadjuvant chemotherapy, supporting the external validity of our population [<xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>]. This offers the encouraging prospect of avoiding unnecessary marker clips, thereby limiting patient inconvenience and potential complications.</p><p id="Par61">The limitations of our study were, first, its retrospective nature, although this was necessary for an initial approach to this issue. Second, a larger number of readers would have enhanced the internal validity of our study and a larger number of patients included would have enhanced the statistic power.</p><p id="Par62">All these results could suggest the following proposition:<list list-type="bullet"><list-item><p id="Par63">For grade 2 tumors with more than 10 calcifications: marker clip placement is optional. <italic>We recommend checking the persistence of micro-calcification after diagnostic macrobiopsy.</italic></p></list-item><list-item><p id="Par64">For grade 3 tumors: marker clip placement is recommended, regardless of the initial number of calcifications in the group.</p></list-item></list></p></sec><sec id="Sec14"><title>Conclusion</title><p id="Par65">Our study suggests that more than 10 microcalcifications in a grade 2 breast tumor at the initial diagnosis may obviate the need for a marker clip.</p><p id="Par66">An external validation study by a randomized clinical trial should be performed to confirm our results.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AIC</term><def><p id="Par5">Akaike information criterion</p></def></def-item><def-item><term>BI-RADS</term><def><p id="Par6">Breast imaging-reporting and data system</p></def></def-item><def-item><term>Ca</term><def><p id="Par7">Calcifications</p></def></def-item><def-item><term>CI</term><def><p id="Par8">Confidence interval</p></def></def-item><def-item><term>ER</term><def><p id="Par9">Estrogen receptor</p></def></def-item><def-item><term>HER2</term><def><p id="Par10">Human epidermal growth factor receptor-2</p></def></def-item><def-item><term>ICNST</term><def><p id="Par11">Invasive carcinoma of no special type</p></def></def-item><def-item><term>ILC</term><def><p id="Par12">Invasive lobular carcinoma</p></def></def-item><def-item><term>OR</term><def><p id="Par13">Odds ratio</p></def></def-item><def-item><term>PR</term><def><p id="Par14">Progesterone receptor</p></def></def-item><def-item><term>SD</term><def><p id="Par15">Standard deviation</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>All authors contributed to the study conception and design. Material preparation, data collection were performed by Henri TALEC and Pierre BERGE, analysis was performed by Catherine GUERIN-CHARBONNEL. The first draft of the manuscript was written by Henri TALEC and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by Universit&#x000e9; d'Angers. The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par67">The authors declare no competing interests.</p></notes><notes id="FPar2"><title>Ethical approval</title><p id="Par68">This study was performed in line with the principles of the Declaration of Helsinki. Access to health information was approved by an ethics committee (#2022-158, Ethic commitee CHU d&#x02019;Angers).</p></notes><notes id="FPar3"><title>Informed consent</title><p id="Par69">Informed consent was obtained from all individual participants included in the study. All patients had approved the re-use of their electronically recorded data.</p></notes><notes id="FPar4"><title>Consent for publication</title><p id="Par70">The authors affirm that human research participants provided informed consent for publication of the images in Figs.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Mauriac</surname><given-names>L</given-names></name><etal/></person-group><article-title>Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124 month median follow up</article-title><source>Ann Oncol</source><year>1999</year><volume>10</volume><issue>1</issue><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1023/a:1008337009350</pub-id><pub-id pub-id-type="pmid">10076721</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Mauriac L et al (1999) Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124 month median follow up. Ann Oncol 10(1):47&#x02013;52. 10.1023/a:1008337009350<pub-id pub-id-type="pmid">10076721</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Cortazar</surname><given-names>P</given-names></name><etal/></person-group><article-title>Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis</article-title><source>Lancet</source><year>2014</year><volume>384</volume><issue>9938</issue><fpage>164</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(13)62422-8</pub-id><pub-id pub-id-type="pmid">24529560</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Cortazar P et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384(9938):164&#x02013;172. 10.1016/S0140-6736(13)62422-8<pub-id pub-id-type="pmid">24529560</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz-Wendtland</surname><given-names>R</given-names></name><etal/></person-group><article-title>Evaluation of a marker clip system in sonographically guided core needle biopsy for breast cancer localization before and after neoadjuvant chemotherapy</article-title><source>Geburtshilfe Frauenheilkd</source><year>2017</year><volume>77</volume><issue>2</issue><fpage>169</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1055/s-0042-124191</pub-id><pub-id pub-id-type="pmid">28331239</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Schulz-Wendtland R et al (2017) Evaluation of a marker clip system in sonographically guided core needle biopsy for breast cancer localization before and after neoadjuvant chemotherapy. Geburtshilfe Frauenheilkd 77(2):169&#x02013;175. 10.1055/s-0042-124191<pub-id pub-id-type="pmid">28331239</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Dash</surname><given-names>N</given-names></name><etal/></person-group><article-title>Usefulness of tissue marker clips in patients undergoing neoadjuvant chemotherapy for breast cancer</article-title><source>AJR Am J Roentgenol</source><year>1999</year><volume>173</volume><issue>4</issue><fpage>911</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.2214/ajr.173.4.10511147</pub-id><pub-id pub-id-type="pmid">10511147</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Dash N et al (1999) Usefulness of tissue marker clips in patients undergoing neoadjuvant chemotherapy for breast cancer. AJR Am J Roentgenol 173(4):911&#x02013;917. 10.2214/ajr.173.4.10511147<pub-id pub-id-type="pmid">10511147</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Shahzad</surname><given-names>R</given-names></name><etal/></person-group><article-title>Sonographically guided metalic clip placement for tumour localization in early breast cancer patients undergoing neoadjuvant chemotherapy</article-title><source>J Pak Med Assoc</source><year>2019</year><volume>69</volume><issue>10</issue><fpage>1501</fpage><lpage>1504</lpage><pub-id pub-id-type="pmid">31622305</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Shahzad R et al (2019) Sonographically guided metalic clip placement for tumour localization in early breast cancer patients undergoing neoadjuvant chemotherapy. J Pak Med Assoc 69(10):1501&#x02013;1504<pub-id pub-id-type="pmid">31622305</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Masroor</surname><given-names>I</given-names></name><etal/></person-group><article-title>Outcome and cost effectiveness of ultrasonographically guided surgical clip placement for tumor localization in patients undergoing neo-adjuvant chemotherapy for breast cancer</article-title><source>Asian Pac J Cancer Prev</source><year>2015</year><volume>16</volume><issue>18</issue><fpage>8339</fpage><lpage>8343</lpage><pub-id pub-id-type="doi">10.7314/apjcp.2015.16.18.8339</pub-id><pub-id pub-id-type="pmid">26745082</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Masroor I et al (2015) Outcome and cost effectiveness of ultrasonographically guided surgical clip placement for tumor localization in patients undergoing neo-adjuvant chemotherapy for breast cancer. Asian Pac J Cancer Prev 16(18):8339&#x02013;8343. 10.7314/apjcp.2015.16.18.8339<pub-id pub-id-type="pmid">26745082</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>The role of mammographic calcification in the neoadjuvant therapy of breast cancer imaging evaluation</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><issue>2</issue><fpage>e88853</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0088853</pub-id><pub-id pub-id-type="pmid">24523942</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Li JJ et al (2014) The role of mammographic calcification in the neoadjuvant therapy of breast cancer imaging evaluation. PLoS ONE 9(2):e88853. 10.1371/journal.pone.0088853<pub-id pub-id-type="pmid">24523942</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Fushimi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Do decreased breast microcalcifications after neoadjuvant chemotherapy predict pathologic complete response?</article-title><source>Clin Breast Cancer</source><year>2020</year><volume>20</volume><issue>1</issue><fpage>e82</fpage><lpage>e88</lpage><pub-id pub-id-type="doi">10.1016/j.clbc.2019.05.015</pub-id><pub-id pub-id-type="pmid">31255548</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Fushimi A et al (2020) Do decreased breast microcalcifications after neoadjuvant chemotherapy predict pathologic complete response? Clin Breast Cancer 20(1):e82&#x02013;e88. 10.1016/j.clbc.2019.05.015<pub-id pub-id-type="pmid">31255548</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>EY</given-names></name><etal/></person-group><article-title>Preoperative evaluation of mammographic microcalcifications after neoadjuvant chemotherapy for breast cancer</article-title><source>Clin Radiol</source><year>2020</year><volume>75</volume><issue>8</issue><fpage>641.e19</fpage><lpage>641.e27</lpage><pub-id pub-id-type="doi">10.1016/j.crad.2020.03.024</pub-id><pub-id pub-id-type="pmid">32291081</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Kim EY et al (2020) Preoperative evaluation of mammographic microcalcifications after neoadjuvant chemotherapy for breast cancer. Clin Radiol 75(8):641.e19-641.e27. 10.1016/j.crad.2020.03.024<pub-id pub-id-type="pmid">32291081</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Iotti</surname><given-names>V</given-names></name><etal/></person-group><article-title>Accuracy and reproducibility of contrast-enhanced mammography in the assessment of response to neoadjuvant chemotherapy in breast cancer patients with calcifications in the tumor bed</article-title><source>Diagnostics</source><year>2021</year><volume>11</volume><issue>3</issue><fpage>435</fpage><pub-id pub-id-type="doi">10.3390/diagnostics11030435</pub-id><pub-id pub-id-type="pmid">33806306</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Iotti V et al (2021) Accuracy and reproducibility of contrast-enhanced mammography in the assessment of response to neoadjuvant chemotherapy in breast cancer patients with calcifications in the tumor bed. Diagnostics 11(3):435. 10.3390/diagnostics11030435<pub-id pub-id-type="pmid">33806306</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Feliciano</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Do calcifications seen on mammography after neoadjuvant chemotherapy for breast cancer always need to be excised?</article-title><source>Ann Surg Oncol</source><year>2017</year><volume>24</volume><issue>6</issue><fpage>1492</fpage><lpage>1498</lpage><pub-id pub-id-type="doi">10.1245/s10434-016-5741-y</pub-id><pub-id pub-id-type="pmid">28058550</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Feliciano Y et al (2017) Do calcifications seen on mammography after neoadjuvant chemotherapy for breast cancer always need to be excised? Ann Surg Oncol 24(6):1492&#x02013;1498. 10.1245/s10434-016-5741-y<pub-id pub-id-type="pmid">28058550</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Yim</surname><given-names>H</given-names></name><etal/></person-group><article-title>Change in microcalcifications on mammography after neoadjuvant chemotherapy in breast cancer patients: correlation with tumor response grade and comparison with lesion extent</article-title><source>Acta Radiol</source><year>2019</year><volume>60</volume><issue>2</issue><fpage>131</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1177/0284185118776491</pub-id><pub-id pub-id-type="pmid">29764199</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Yim H et al (2019) Change in microcalcifications on mammography after neoadjuvant chemotherapy in breast cancer patients: correlation with tumor response grade and comparison with lesion extent. Acta Radiol 60(2):131&#x02013;139. 10.1177/0284185118776491<pub-id pub-id-type="pmid">29764199</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Yeong</surname><given-names>YA</given-names></name><etal/></person-group><article-title>Residual microcalcifications after neoadjuvant chemotherapy for locally advanced breast cancer: comparison of the accuracies of mammography and MRI in predicting pathological residual tumor</article-title><source>World J Surg Oncol</source><year>2017</year><volume>15</volume><issue>1</issue><fpage>198</fpage><pub-id pub-id-type="doi">10.1186/s12957-017-1263-8</pub-id><pub-id pub-id-type="pmid">29110671</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Yeong YA et al (2017) Residual microcalcifications after neoadjuvant chemotherapy for locally advanced breast cancer: comparison of the accuracies of mammography and MRI in predicting pathological residual tumor. World J Surg Oncol 15(1):198. 10.1186/s12957-017-1263-8<pub-id pub-id-type="pmid">29110671</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>Y-S</given-names></name><etal/></person-group><article-title>Residual mammographic microcalcifications and enhancing lesions on MRI after neoadjuvant systemic chemotherapy for locally advanced breast cancer: correlation with histopathologic residual tumor size</article-title><source>Ann Surg Oncol</source><year>2016</year><volume>23</volume><issue>4</issue><fpage>1135</fpage><lpage>1142</lpage><pub-id pub-id-type="doi">10.1245/s10434-015-4993-2</pub-id><pub-id pub-id-type="pmid">26628432</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Kim Y-S et al (2016) Residual mammographic microcalcifications and enhancing lesions on MRI after neoadjuvant systemic chemotherapy for locally advanced breast cancer: correlation with histopathologic residual tumor size. Ann Surg Oncol 23(4):1135&#x02013;1142. 10.1245/s10434-015-4993-2<pub-id pub-id-type="pmid">26628432</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Noguera</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Mammographic findings in microcalcifications associated with breast cancer after neoadjuvant chemotherapy</article-title><source>Radiologia</source><year>2007</year><volume>49</volume><issue>1</issue><fpage>37</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/s0033-8338(07)73714-1</pub-id><pub-id pub-id-type="pmid">17397619</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Noguera JJ et al (2007) Mammographic findings in microcalcifications associated with breast cancer after neoadjuvant chemotherapy. Radiologia 49(1):37&#x02013;41. 10.1016/s0033-8338(07)73714-1<pub-id pub-id-type="pmid">17397619</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Youn</surname><given-names>I</given-names></name><etal/></person-group><article-title>Ultrasonography-guided surgical clip placement for tumor localization in patients undergoing neoadjuvant chemotherapy for breast cancer</article-title><source>J Breast Cancer</source><year>2015</year><volume>18</volume><issue>1</issue><fpage>44</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.4048/jbc.2015.18.1.44</pub-id><pub-id pub-id-type="pmid">25834610</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Youn I et al (2015) Ultrasonography-guided surgical clip placement for tumor localization in patients undergoing neoadjuvant chemotherapy for breast cancer. J Breast Cancer 18(1):44&#x02013;49. 10.4048/jbc.2015.18.1.44<pub-id pub-id-type="pmid">25834610</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Jarazb</surname><given-names>M</given-names></name><etal/></person-group><article-title>Association of breast cancer grade with response to neoadjuvant chemotherapy assessed postoperatively</article-title><source>Pol J Pathol</source><year>2019</year><volume>70</volume><issue>2</issue><fpage>91</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.5114/pjp.2019.87101</pub-id><pub-id pub-id-type="pmid">31556559</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Jarazb M et al (2019) Association of breast cancer grade with response to neoadjuvant chemotherapy assessed postoperatively. Pol J Pathol 70(2):91&#x02013;99. 10.5114/pjp.2019.87101<pub-id pub-id-type="pmid">31556559</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>BR</given-names></name><etal/></person-group><article-title>Microcalcifications and peritumoral edema predict survival outcome in luminal breast cancer treated with neoadjuvant chemotherapy</article-title><source>Radiology</source><year>2022</year><volume>304</volume><issue>2</issue><fpage>310</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1148/radiol.211509</pub-id><pub-id pub-id-type="pmid">35536129</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Kwon BR et al (2022) Microcalcifications and peritumoral edema predict survival outcome in luminal breast cancer treated with neoadjuvant chemotherapy. Radiology 304(2):310&#x02013;319. 10.1148/radiol.211509<pub-id pub-id-type="pmid">35536129</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J</given-names></name><etal/></person-group><article-title>Oncologic necessity for the complete removal of residual microcalcifications after neoadjuvant chemotherapy for breast cancer</article-title><source>Sci Rep</source><year>2022</year><volume>12</volume><issue>1</issue><fpage>21535</fpage><pub-id pub-id-type="doi">10.1038/s41598-022-24757-7</pub-id><pub-id pub-id-type="pmid">36513704</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Lee J et al (2022) Oncologic necessity for the complete removal of residual microcalcifications after neoadjuvant chemotherapy for breast cancer. Sci Rep 12(1):21535. 10.1038/s41598-022-24757-7<pub-id pub-id-type="pmid">36513704</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>A</given-names></name><etal/></person-group><article-title>Are baseline mammographic and ultrasound features associated with metastasis free survival in women receiving neoadjuvant chemotherapy for invasive breast cancer?</article-title><source>Eur J Radiol</source><year>2021</year><volume>141</volume><fpage>109790</fpage><pub-id pub-id-type="doi">10.1016/j.ejrad.2021.109790</pub-id><pub-id pub-id-type="pmid">34091135</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Evans A et al (2021) Are baseline mammographic and ultrasound features associated with metastasis free survival in women receiving neoadjuvant chemotherapy for invasive breast cancer? Eur J Radiol 141:109790. 10.1016/j.ejrad.2021.109790<pub-id pub-id-type="pmid">34091135</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>